Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2022 | Molecular markers guiding treatment approaches in bladder cancer

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, reflects on key areas of unmet need in bladder cancer research, including the importance of molecular markers to guide personalized treatment approaches. Novel targeted therapies such as enfortumab vedotin, erdafitinib and sacitizumab govetican are being moved to earlier lines of treatment, highlighting the importance of patient stratification. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.